Tags

Type your tag names separated by a space and hit enter

Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Int J Urol. 2006 Apr; 13(4):401-8.IJ

Abstract

AIM

The expression of the telomerase subunits such as human telomerase reverse transcriptase (hTERT) and human telomerase RNA component (hTR) may be associated with tumor development and progression. We evaluated the relationship between mRNA quantification of both hTERT and hTR and clinicopathologic parameters in bladder cancer.

METHODS

We examined the mRNA expression of hTERT and hTR in 29 specimens with bladder cancer (Grade: Grade I, 9 cases; Grade II, 13 cases and Grade III, 7 cases. Stage: pTa-pT1, 18 cases; pT2-T4, 11 cases). We immediately froze all of specimens obtained during TUR-Bt and isolated the total RNA from each specimen. We measured the quantity of hTERT, hTR and GAPDH mRNA by a real-time reverse transcription-polymerase chain reaction method based on TaqMan technology.

RESULTS

The hTERT/GAPDH mRNA ratio and hTERT mRNA/total RNA in superficial bladder tumor was significantly lower than in invasive bladder tumor. The hTR/GAPDH mRNA ratio and hTR mRNA/total RNA in superficial tumor were significantly lower than in invasive bladder tumor. The hTERT mRNA expression significantly correlated with tumor grade, but the hTR mRNA expression did not correlate with tumor grade. There was no significant difference in the hTERT/GAPDH mRNA ratio and hTR mRNA/total RNA according to multiplicity of bladder tumor.

CONCLUSIONS

Our results demonstrated that the expression of hTERT mRNA correlated with the progression of stage and grade in bladder cancer. The quantitative analysis of hTERT and hTR mRNA might be a marker for clinicopathologic parameters in bladder cancer.

Authors+Show Affiliations

Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan. takihana@yamanashi.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16734859

Citation

Takihana, Yoshio, et al. "Real-time Quantitative Analysis for Human Telomerase Reverse Transcriptase mRNA and Human Telomerase RNA Component mRNA Expressions as Markers for Clinicopathologic Parameters in Urinary Bladder Cancer." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 13, no. 4, 2006, pp. 401-8.
Takihana Y, Tsuchida T, Fukasawa M, et al. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Int J Urol. 2006;13(4):401-8.
Takihana, Y., Tsuchida, T., Fukasawa, M., Araki, I., Tanabe, N., & Takeda, M. (2006). Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. International Journal of Urology : Official Journal of the Japanese Urological Association, 13(4), 401-8.
Takihana Y, et al. Real-time Quantitative Analysis for Human Telomerase Reverse Transcriptase mRNA and Human Telomerase RNA Component mRNA Expressions as Markers for Clinicopathologic Parameters in Urinary Bladder Cancer. Int J Urol. 2006;13(4):401-8. PubMed PMID: 16734859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. AU - Takihana,Yoshio, AU - Tsuchida,Takayuki, AU - Fukasawa,Mizuya, AU - Araki,Isao, AU - Tanabe,Nobuaki, AU - Takeda,Masayuki, PY - 2006/6/1/pubmed PY - 2006/10/25/medline PY - 2006/6/1/entrez SP - 401 EP - 8 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int. J. Urol. VL - 13 IS - 4 N2 - AIM: The expression of the telomerase subunits such as human telomerase reverse transcriptase (hTERT) and human telomerase RNA component (hTR) may be associated with tumor development and progression. We evaluated the relationship between mRNA quantification of both hTERT and hTR and clinicopathologic parameters in bladder cancer. METHODS: We examined the mRNA expression of hTERT and hTR in 29 specimens with bladder cancer (Grade: Grade I, 9 cases; Grade II, 13 cases and Grade III, 7 cases. Stage: pTa-pT1, 18 cases; pT2-T4, 11 cases). We immediately froze all of specimens obtained during TUR-Bt and isolated the total RNA from each specimen. We measured the quantity of hTERT, hTR and GAPDH mRNA by a real-time reverse transcription-polymerase chain reaction method based on TaqMan technology. RESULTS: The hTERT/GAPDH mRNA ratio and hTERT mRNA/total RNA in superficial bladder tumor was significantly lower than in invasive bladder tumor. The hTR/GAPDH mRNA ratio and hTR mRNA/total RNA in superficial tumor were significantly lower than in invasive bladder tumor. The hTERT mRNA expression significantly correlated with tumor grade, but the hTR mRNA expression did not correlate with tumor grade. There was no significant difference in the hTERT/GAPDH mRNA ratio and hTR mRNA/total RNA according to multiplicity of bladder tumor. CONCLUSIONS: Our results demonstrated that the expression of hTERT mRNA correlated with the progression of stage and grade in bladder cancer. The quantitative analysis of hTERT and hTR mRNA might be a marker for clinicopathologic parameters in bladder cancer. SN - 0919-8172 UR - https://www.unboundmedicine.com/medline/citation/16734859/Real_time_quantitative_analysis_for_human_telomerase_reverse_transcriptase_mRNA_and_human_telomerase_RNA_component_mRNA_expressions_as_markers_for_clinicopathologic_parameters_in_urinary_bladder_cancer_ L2 - https://doi.org/10.1111/j.1442-2042.2006.01300.x DB - PRIME DP - Unbound Medicine ER -